Atlas Trials

Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer

Clinical trial NCT06734182 · RECRUITING

Trial details

NCT number
NCT06734182
Sponsor
Guangdong Provincial People's Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Non-small Cell Lung Cancer
Start date
2024-06-22
Primary completion
2027-06-22
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.